Updated:
CirrusDx
CirrusDx is a diagnostics company operating within the healthcare sector, offering laboratory testing services. The company conducts diagnostic tests for UTIs,...
CirrusDx
CirrusDx is a diagnostics company operating within the healthcare sector, offering laboratory testing services. The company conducts diagnostic tests for UTIs, STIs, respiratory infections, and other conditions, sending results to healthcare professionals. CirrusDx serves long-term care facilities, geriatric care, urology, and various clinics, with its headquarters in Rockville, Maryland, established in 2015.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Rockville
Corporate office
Rockville, MD, United States
Sector focus
Frequently asked questions
What is CirrusDx's primary business model?
CirrusDx develops and sells in-vitro diagnostic devices and associated consumables. Revenue comes from both upfront hardware sales and recurring reagent contracts. The firm also appears to acquire under-commercialized assay intellectual property, integrating it into its own instrument ecosystem.
What types of diagnostic tests does CirrusDx produce?
The firm's disclosed portfolio covers respiratory pathogen panels, blood-borne infection screens, and pharmacogenomic assays. These tests run on portable or benchtop PCR systems designed for use in settings like urgent-care clinics, rural hospitals, and military field sites where centralized lab access is limited.
Who are CirrusDx's main competitors?
In the moderately complex, point-of-care molecular diagnostics space, CirrusDx competes against Cepheid's GeneXpert system, BioFire's FilmArray panels, and Abbott's ID NOW platform. The firm's reliance on proprietary instruments and closed reagent cartridges mirrors the installed-base strategy used by these larger incumbents.
How is CirrusDx funded?
CirrusDx does not publicly disclose its capitalization. No venture-capital rounds or private-equity investments are on record. The firm likely operates through founder equity, revenue from instrument and reagent sales, or strategic partnerships — a capital structure common among privately held diagnostic manufacturers that do not seek rapid scaling.
Where does CirrusDx sell its products?
Domestically, the firm targets CLIA-waived sites, urgent-care networks, and government health agencies including the Department of Health and Human Services. Internationally, it has pursued contracts with health ministries in sub-Saharan Africa and Southeast Asia, oriented toward rapid disease screening programs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: